ESH AL 2024 | Challenges associated with treating BPDCN: the rarity of the disease
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights the challenges associated with treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Due to the rarity of the disease, Dr Lane emphasizes the crucial role of international collaboration in recruiting patients for clinical trial research. This interview took place at the 4th European School of Hematology Acute Leukemia (ESH AL) congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Cimeio Therapeutics: Consultant; IDRx: Consultant; Jnana Therapeutics: Consultant; ProteinQure: Consultant; Qiagen: Consultant; Medzown: Stokeholder, SAB; AbbVie: Research Support; Stemline Therapeutics: Research Support.
